@article{JTD17115,
author = {Hai-Yan Tu and Qi Zhang and Yi-Long Wu},
title = {Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed},
journal = {Journal of Thoracic Disease},
volume = {9},
number = {12},
year = {2017},
keywords = {},
abstract = {The advent of programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) checkpoint inhibitors has made dramatic progress for the treatment of non-small cell lung cancer (NSCLC). In several series of clinical studies, anti-PD-1/PD-L1 antibodies have generated durable effects, leading to long-term survival with manageable toxicity for patients with advanced NSCLC (1-6). The potential of these agents to generate durable clinical responses has led to their rapid uptake as standard therapy.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/17115}
}